Startup profile for Marrow Therapeutics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Marrow Therapeutics funding, valuation and investors

Preclinical in-vivo genetic medicines targeting bone marrow in sickle-cell disease and beta thalassemia.

Verified company research · funding, investors and latest developments

Keep track of Marrow Therapeutics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A (historical closing date not disclosed; revealed November 17, 2026)

$53M · Date not disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$173M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · Watertown, Massachusetts, United States

Investors in latest funding

Lead: Scion Life Sciences , venBio

Sources: latest funding · marrowtx.com Last verified: 2026-11-18T00:00:00.000Z

Overview

Founded by Scion Life Sciences, Watertown-based Marrow Therapeutics develops Transferrin Antibody Bioconjugate (TAB) technology. Its engineered antibody targets transferrin receptor TfR1 to ferry therapeutic oligonucleotides toward bone marrow, aiming to suppress BCL11A and reactivate fetal hemoglobin. MAR-101 is in IND-enabling studies, not human treatment or an approved product.

A research-stage development sequence comprises target and payload optimization, assessment of marrow uptake, nonclinical efficacy and off-target/anemia risks, manufacturing and toxicology qualification, an investigational regulatory submission, and eventual clinical safety and efficacy trials if permitted. Success for sickle-cell disease or beta thalassemia remains unproven.

Current management options can include transfusions, disease-modifying therapy, transplant and approved ex-vivo gene therapies for eligible people; do not infer an in-vivo clinical advantage yet. The November 17, 2026 launch disclosed a $53M earlier Series A co-led by Scion and venBio and a separate $120M earlier Series B led by OrbiMed. Actual dates of those closes were not stated.

The combined $173M is not a third round or entirely new capital raised on launch day. Investors, mechanism and scientific programme are documented in the issuer's release and pipeline pages. No valuation, commercial pricing, revenue or demonstrated patient benefit has been disclosed.

Why Marrow Therapeutics is interesting

The company disclosed two distinct financing tranches totaling $173M and a tissue-targeted antibody-cargo approach that still faces demanding clinical and anemia-safety validation.

Product & use cases

Investigational TAB antibody-linked TfR1 marrow-targeting cargo to reduce BCL11A and increase fetal hemoglobin. MAR-101 IND-enabling, no clinical trial or regulatory approval yet.

  • Potential research therapy for sickle-cell disease.
  • Potential research therapy for beta thalassemia.
  • Earlier discovery programs for additional marrow and hematological disorders.

Key facts

  • $173M is $53M Series A plus $120M Series B, not a separate financing.
  • The original close dates remain undisclosed; November 17 is disclosure date.
  • Lead candidate is preclinical IND-enabling, with TfR1 off-target anemia risk to address.

Funding history (newest first)

Series A (historical closing date not disclosed; revealed November 17, 2026)

$53M

Source: Read source · marrowtx.com

Series B (historical closing date not disclosed; revealed November 17, 2026)

$120M
  • OrbiMed (lead)
  • RTW Investments (participant)
  • Surveyor Capital (participant)
  • KKR (participant)

Source: Read source · marrowtx.com

Investors in our directory

Funds linked from Marrow Therapeutics's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

  • Vertex/CRISPR Therapeutics Casgevy alternative

    Approved ex-vivo gene editing for eligible patients; different administration, maturity and risks.

  • Bluebird bio Lyfgenia alternative

    Ex-vivo gene therapy option requiring specialized treatment logistics.

  • Transfusions and disease-modifying medicines incumbent

    Existing management routes; effectiveness comparisons require human trial data.

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.